JP2017532294A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017532294A5 JP2017532294A5 JP2017510289A JP2017510289A JP2017532294A5 JP 2017532294 A5 JP2017532294 A5 JP 2017532294A5 JP 2017510289 A JP2017510289 A JP 2017510289A JP 2017510289 A JP2017510289 A JP 2017510289A JP 2017532294 A5 JP2017532294 A5 JP 2017532294A5
- Authority
- JP
- Japan
- Prior art keywords
- och
- phenyl
- compound
- chch
- sch
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 33
- -1 methoxyphenyl Chemical group 0.000 claims 19
- 150000001875 compounds Chemical class 0.000 claims 16
- 150000003839 salts Chemical class 0.000 claims 14
- GVNVAWHJIKLAGL-UHFFFAOYSA-N 2-(cyclohexen-1-yl)cyclohexan-1-one Chemical compound O=C1CCCCC1C1=CCCCC1 GVNVAWHJIKLAGL-UHFFFAOYSA-N 0.000 claims 11
- 101150065749 Churc1 gene Proteins 0.000 claims 11
- 102100038239 Protein Churchill Human genes 0.000 claims 11
- 125000004076 pyridyl group Chemical group 0.000 claims 9
- 125000001424 substituent group Chemical group 0.000 claims 8
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims 7
- 125000000217 alkyl group Chemical group 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 125000001544 thienyl group Chemical group 0.000 claims 4
- 125000001207 fluorophenyl group Chemical group 0.000 claims 3
- 125000003566 oxetanyl group Chemical group 0.000 claims 3
- 125000004430 oxygen atom Chemical group O* 0.000 claims 3
- 125000003373 pyrazinyl group Chemical group 0.000 claims 3
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 3
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims 3
- 125000003003 spiro group Chemical group 0.000 claims 3
- 125000000335 thiazolyl group Chemical group 0.000 claims 3
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 2
- 101100167062 Caenorhabditis elegans chch-3 gene Proteins 0.000 claims 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 125000002883 imidazolyl group Chemical group 0.000 claims 2
- 125000003226 pyrazolyl group Chemical group 0.000 claims 2
- 125000005869 (methoxyethoxy)methanyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])OC([H])([H])* 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 claims 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 claims 1
- 208000037976 chronic inflammation Diseases 0.000 claims 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 claims 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 125000003944 tolyl group Chemical group 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462039622P | 2014-08-20 | 2014-08-20 | |
| US62/039,622 | 2014-08-20 | ||
| PCT/US2015/046005 WO2016028959A1 (en) | 2014-08-20 | 2015-08-20 | Substituted bicyclic compounds |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017532294A JP2017532294A (ja) | 2017-11-02 |
| JP2017532294A5 true JP2017532294A5 (https=) | 2018-09-27 |
| JP6607924B2 JP6607924B2 (ja) | 2019-11-20 |
Family
ID=54012322
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017510289A Active JP6607924B2 (ja) | 2014-08-20 | 2015-08-20 | 置換二環式化合物 |
Country Status (34)
| Country | Link |
|---|---|
| US (6) | US9522888B2 (https=) |
| EP (1) | EP3183242B1 (https=) |
| JP (1) | JP6607924B2 (https=) |
| KR (1) | KR102559465B1 (https=) |
| CN (1) | CN107148409B (https=) |
| AR (1) | AR101591A1 (https=) |
| AU (1) | AU2015305501B2 (https=) |
| CA (1) | CA2958560C (https=) |
| CL (1) | CL2017000382A1 (https=) |
| CO (1) | CO2017002312A2 (https=) |
| CY (1) | CY1124355T1 (https=) |
| DK (1) | DK3183242T3 (https=) |
| EA (1) | EA032415B1 (https=) |
| ES (1) | ES2877627T3 (https=) |
| HR (1) | HRP20211121T1 (https=) |
| HU (1) | HUE055567T2 (https=) |
| IL (1) | IL250613B (https=) |
| LT (1) | LT3183242T (https=) |
| MA (1) | MA40082B1 (https=) |
| MX (1) | MX381458B (https=) |
| MY (1) | MY179783A (https=) |
| PE (1) | PE20170445A1 (https=) |
| PH (1) | PH12017500261A1 (https=) |
| PL (1) | PL3183242T3 (https=) |
| PT (1) | PT3183242T (https=) |
| RS (1) | RS62118B1 (https=) |
| SG (1) | SG11201701221SA (https=) |
| SI (1) | SI3183242T1 (https=) |
| SM (1) | SMT202100391T1 (https=) |
| TN (1) | TN2017000026A1 (https=) |
| TW (1) | TWI689487B (https=) |
| UY (1) | UY36274A (https=) |
| WO (1) | WO2016028959A1 (https=) |
| ZA (1) | ZA201701210B (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI689487B (zh) * | 2014-08-20 | 2020-04-01 | 美商必治妥美雅史谷比公司 | 經取代雙環化合物 |
| ES2859478T3 (es) * | 2016-09-02 | 2021-10-04 | Bristol Myers Squibb Co | Compuestos heterocíclicos tricíclicos sustituidos |
| IL271149B2 (en) * | 2017-06-14 | 2024-05-01 | Trevena Inc | Compounds for modulating s1p1 activity and methods of using the same |
| WO2019032631A1 (en) * | 2017-08-09 | 2019-02-14 | Bristol-Myers Squibb Company | Oxime ether compounds |
| US11046646B2 (en) | 2017-08-09 | 2021-06-29 | Bristol-Myers Squibb Company | Alkylphenyl compounds |
| EP4061352A4 (en) | 2019-11-19 | 2024-02-28 | Trevena, Inc. | COMPOUNDS AND METHODS FOR PRODUCING S1P1-MODULATING COMPOUNDS |
| FI4126829T3 (fi) * | 2020-03-27 | 2026-04-01 | Receptos Llc | Sfingosiini 1 -fosfaattireseptorin modulaattoreita |
| CN116903578B (zh) * | 2023-09-04 | 2023-11-24 | 江西省药品检验检测研究院 | 连钱草中的酚酸类化合物及其提取分离方法与应用 |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4200750A (en) | 1977-01-07 | 1980-04-29 | Westwood Pharmaceuticals Inc. | 4-Substituted imidazo [1,2-a]quinoxalines |
| US6069143A (en) | 1994-12-20 | 2000-05-30 | Smithkline Beecham Corporation | Fibrinogen receptor antagonists |
| US20050070506A1 (en) | 2002-01-18 | 2005-03-31 | Doherty George A. | Selective s1p1/edg1 receptor agonists |
| ATE448193T1 (de) | 2002-01-18 | 2009-11-15 | Merck & Co Inc | ßN-(BENZYL)AMINOALKYL CARBOXYLATE, PHOSPHINATE, PHOSPHONATE UND TETRAZOLE ALS EDG REZEPTORAGONISTENß |
| US7479504B2 (en) | 2002-01-18 | 2009-01-20 | Merck & Co., Inc. | Edg receptor agonists |
| US7309721B2 (en) | 2002-03-01 | 2007-12-18 | Merck + Co., Inc. | Aminoalkylphosphonates and related compounds as Edg receptor agonists |
| JP2005533058A (ja) | 2002-06-17 | 2005-11-04 | メルク エンド カムパニー インコーポレーテッド | Ｅｄｇ受容体アゴニストとしての１−（（５−アリール−１，２，４−オキサジアゾール−３−イル）ベンジル）アゼチジン−３−カルボキシラートおよび１−（（５−アリール−１，２，４−オキサジアゾール−３−イル）ベンジル）ピロリジン−３−カルボキシラート |
| BRPI0410439A (pt) | 2003-05-19 | 2006-06-06 | Irm Llc | compostos e composições imunossupressoras |
| US7605171B2 (en) | 2003-12-17 | 2009-10-20 | Merck & Co., Inc. | (3,4-disubstituted)propanoic carboxylates as S1P (Edg) receptor agonists |
| TW200538433A (en) | 2004-02-24 | 2005-12-01 | Irm Llc | Immunosuppressant compounds and compositiions |
| AU2005299851B2 (en) | 2004-10-22 | 2011-03-17 | Merck Sharp & Dohme Corp. | 2-(aryl)azacyclylmethyl carboxylates, sulfonates, phosphonates, phosphinates and heterocycles as S1P receptor agonists |
| AU2006214314B2 (en) * | 2005-02-14 | 2012-02-09 | University Of Virginia Patent Foundation | Sphingosine 1- phos phate agonists comprising cycloalkanes and 5 -membered heterocycles substituted by amino and phenyl groups |
| CN101193852A (zh) | 2005-02-18 | 2008-06-04 | 因诺迪亚有限公司 | 4-羟基异亮氨酸类似物及其用途 |
| EP1858889A1 (en) | 2005-03-08 | 2007-11-28 | Biota Scientific Management Pty. Ltd. | Bicyclic nucleosides and nucleotides as therapeutic agents |
| BRPI0609668A2 (pt) | 2005-03-23 | 2011-10-18 | Actelion Pharmaceuticals Ltd | composto, composição farmacêutica, e, uso de um composto |
| CN101203512A (zh) | 2005-04-22 | 2008-06-18 | 第一三共株式会社 | 杂环化合物 |
| BRPI0612028A2 (pt) | 2005-06-08 | 2010-10-13 | Novartis Ag | oxadiazóis ou isodiazóis policìclicos e uso dos mesmos como ligantes de receptor s1p |
| WO2007024922A1 (en) | 2005-08-23 | 2007-03-01 | Irm Llc | Immunosuppressant compounds and compositions |
| US20070203111A1 (en) | 2006-01-06 | 2007-08-30 | Sepracor Inc. | Cycloalkylamines as monoamine reuptake inhibitors |
| KR20080086546A (ko) | 2006-01-27 | 2008-09-25 | 유니버시티 오브 버지니아 페이턴트 파운데이션 | 신경병증성 통증의 치료 방법 |
| WO2007088450A2 (en) | 2006-02-01 | 2007-08-09 | Pfizer Products Inc. | Chromane antagonist of the h-3 receptor |
| JP2009530389A (ja) | 2006-03-21 | 2009-08-27 | エピックス デラウェア， インコーポレイテッド | Ｓ１ｐ受容体調節化合物及びその使用 |
| US7989472B2 (en) | 2006-03-23 | 2011-08-02 | Merck Sharp & Dohme Corp. | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use |
| MX2008012738A (es) | 2006-04-03 | 2009-02-06 | Astellas Pharma Inc | Heterocompuesto. |
| JP2009269819A (ja) | 2006-08-25 | 2009-11-19 | Asahi Kasei Pharma Kk | アミン化合物 |
| ES2400163T3 (es) | 2006-09-08 | 2013-04-08 | Actelion Pharmaceuticals Ltd. | Derivados de piridil-3-ilo como agentes de inmunomodulación |
| GB0625648D0 (en) | 2006-12-21 | 2007-01-31 | Glaxo Group Ltd | Compounds |
| CL2007003784A1 (es) * | 2006-12-21 | 2008-06-27 | Abbott Lab | Compuestos derivados de 1-amino-3-fenilciclopentano, que son agonistas o antagonistas de uno o mas receptores de la familia s1p; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar la esclerosis multiple, artritis reumato |
| CN101610674A (zh) * | 2006-12-21 | 2009-12-23 | 艾博特公司 | 鞘氨醇-1-磷酸酯受体激动剂和拮抗剂化合物 |
| US8217027B2 (en) | 2006-12-21 | 2012-07-10 | Abbott Laboratories | Sphingosine-1-phosphate receptor agonist and antagonist compounds |
| PT2125797E (pt) | 2007-03-16 | 2014-03-11 | Actelion Pharmaceuticals Ltd | Derivados aminopiridina como agonistas do receptor s1p1/edg1 |
| ES2622423T3 (es) | 2007-10-04 | 2017-07-06 | Merck Serono S.A. | Derivados de oxadiazol |
| RU2010121969A (ru) | 2007-11-01 | 2011-12-10 | Актелион Фармасьютиклз Лтд (Ch) | Новые производные пиримидина |
| GB0725105D0 (en) | 2007-12-21 | 2008-01-30 | Glaxo Group Ltd | Compounds |
| PE20091339A1 (es) | 2007-12-21 | 2009-09-26 | Glaxo Group Ltd | Derivados de oxadiazol con actividad sobre receptores s1p1 |
| US8153686B2 (en) | 2008-04-01 | 2012-04-10 | Theravance, Inc. | Amino- and amido-aminotetralin derivatives and related compounds as mu opioid receptor antagonists |
| WO2010042998A1 (en) | 2008-10-17 | 2010-04-22 | Akaal Pharma Pty Ltd | S1p receptors modulators |
| US20100160369A1 (en) | 2008-12-04 | 2010-06-24 | Exelixis, Inc. | S1P1 Agonists and Methods of Making And Using |
| WO2010069949A1 (en) | 2008-12-18 | 2010-06-24 | Merck Serono S.A. | Oxadiazole fused heterocyclic derivatives useful for the treatment of multiple sclerosis |
| EP2202232A1 (en) | 2008-12-26 | 2010-06-30 | Laboratorios Almirall, S.A. | 1,2,4-oxadiazole derivatives and their therapeutic use |
| EP2210890A1 (en) | 2009-01-19 | 2010-07-28 | Almirall, S.A. | Oxadiazole derivatives as S1P1 receptor agonists |
| EP2389377B1 (en) | 2009-01-23 | 2014-07-16 | Bristol-Myers Squibb Company | Substituted oxadiazole derivatives as s1p agonists in the treatment of autoimmune and inflammatory diseases |
| ES2405054T3 (es) | 2009-01-23 | 2013-05-30 | Bristol-Myers Squibb Company | Derivados de pirazol-1,2,4-oxadiazol como agonistas de esfingosina-1-fosfato |
| JP2012515787A (ja) | 2009-01-23 | 2012-07-12 | ブリストル−マイヤーズ スクイブ カンパニー | 自己免疫疾患および炎症性疾患の処置におけるｓ１ｐアゴニストとしての置換オキサジアゾール誘導体 |
| JP2012517445A (ja) | 2009-02-10 | 2012-08-02 | アボット・ラボラトリーズ | Ｓ１ｐ受容体アゴニストおよびアンタゴニストを調製するための方法 |
| US8399451B2 (en) | 2009-08-07 | 2013-03-19 | Bristol-Myers Squibb Company | Heterocyclic compounds |
| JP5728487B2 (ja) * | 2009-10-29 | 2015-06-03 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 三環式ヘテロ環化合物 |
| TW201130488A (en) * | 2010-02-03 | 2011-09-16 | Daiichi Sankyo Co Ltd | Pyrrole compound |
| WO2011133734A1 (en) | 2010-04-23 | 2011-10-27 | Bristol-Myers Squibb Company | 4 - (5 - isoxazolyl or 5 - pyrrazolyl -1,2,4- oxadiazol - 3 - yl) -mandelic acid amides as sphingosin- 1 - phosphate 1 rreceptor agonists |
| CN102260617B (zh) | 2010-05-25 | 2013-11-13 | 张孝忠 | 一种王浆特制酒及其制作工艺 |
| CN102260177A (zh) | 2010-05-25 | 2011-11-30 | 中国医学科学院药物研究所 | 丙二醇类衍生物、其制备方法和其药物组合物与用途 |
| JP5788507B2 (ja) | 2010-07-20 | 2015-09-30 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 置換３−フェニル−１，２，４−オキサジアゾール化合物 |
| EP2619190B1 (en) | 2010-09-24 | 2015-08-12 | Bristol-Myers Squibb Company | Substituted oxadiazole compounds and their use as s1p1 agonists |
| WO2012061459A1 (en) | 2010-11-03 | 2012-05-10 | Bristol-Myers Squibb Company | Heterocyclic compounds as s1p1 agonists for the treatment of autoimmune and vascular diseases |
| CN102250035A (zh) | 2011-06-10 | 2011-11-23 | 北京富卡生物技术有限公司 | 二芳基取代-1，3，4-噁二唑化合物的合成方法和其药物用途 |
| JP5984051B2 (ja) | 2012-07-12 | 2016-09-06 | 株式会社Ｇｓユアサ | 電極体 |
| EA027809B1 (ru) | 2012-07-27 | 2017-09-29 | Биоген Айдек Ма Инк. | Соединения, которые являются s1p-модулирующими агентами и/или atx-модулирующими агентами |
| TWI613182B (zh) * | 2013-02-21 | 2018-02-01 | 必治妥美雅史谷比公司 | 雙環化合物 |
| TWI689487B (zh) * | 2014-08-20 | 2020-04-01 | 美商必治妥美雅史谷比公司 | 經取代雙環化合物 |
-
2015
- 2015-08-19 TW TW104127046A patent/TWI689487B/zh not_active IP Right Cessation
- 2015-08-19 MA MA40082A patent/MA40082B1/fr unknown
- 2015-08-19 AR ARP150102669A patent/AR101591A1/es unknown
- 2015-08-19 UY UY0001036274A patent/UY36274A/es not_active Application Discontinuation
- 2015-08-20 PE PE2017000226A patent/PE20170445A1/es unknown
- 2015-08-20 SI SI201531645T patent/SI3183242T1/sl unknown
- 2015-08-20 HU HUE15756772A patent/HUE055567T2/hu unknown
- 2015-08-20 AU AU2015305501A patent/AU2015305501B2/en active Active
- 2015-08-20 TN TN2017000026A patent/TN2017000026A1/en unknown
- 2015-08-20 PT PT157567728T patent/PT3183242T/pt unknown
- 2015-08-20 KR KR1020177007115A patent/KR102559465B1/ko active Active
- 2015-08-20 CA CA2958560A patent/CA2958560C/en active Active
- 2015-08-20 LT LTEP15756772.8T patent/LT3183242T/lt unknown
- 2015-08-20 RS RS20210902A patent/RS62118B1/sr unknown
- 2015-08-20 MX MX2017001855A patent/MX381458B/es unknown
- 2015-08-20 ES ES15756772T patent/ES2877627T3/es active Active
- 2015-08-20 MY MYPI2017700513A patent/MY179783A/en unknown
- 2015-08-20 EA EA201790427A patent/EA032415B1/ru not_active IP Right Cessation
- 2015-08-20 PL PL15756772T patent/PL3183242T3/pl unknown
- 2015-08-20 DK DK15756772.8T patent/DK3183242T3/da active
- 2015-08-20 SG SG11201701221SA patent/SG11201701221SA/en unknown
- 2015-08-20 US US14/831,439 patent/US9522888B2/en active Active
- 2015-08-20 JP JP2017510289A patent/JP6607924B2/ja active Active
- 2015-08-20 CN CN201580056555.0A patent/CN107148409B/zh active Active
- 2015-08-20 EP EP15756772.8A patent/EP3183242B1/en active Active
- 2015-08-20 WO PCT/US2015/046005 patent/WO2016028959A1/en not_active Ceased
- 2015-08-20 SM SM20210391T patent/SMT202100391T1/it unknown
- 2015-08-20 HR HRP20211121TT patent/HRP20211121T1/hr unknown
-
2016
- 2016-10-28 US US15/337,843 patent/US9770459B2/en active Active
-
2017
- 2017-02-13 PH PH12017500261A patent/PH12017500261A1/en unknown
- 2017-02-15 CL CL2017000382A patent/CL2017000382A1/es unknown
- 2017-02-15 IL IL250613A patent/IL250613B/en active IP Right Grant
- 2017-02-17 ZA ZA2017/01210A patent/ZA201701210B/en unknown
- 2017-03-08 CO CONC2017/0002312A patent/CO2017002312A2/es unknown
- 2017-07-12 US US15/648,250 patent/US10166249B2/en active Active
-
2018
- 2018-11-13 US US16/188,444 patent/US10709719B2/en active Active
-
2020
- 2020-05-21 US US16/879,824 patent/US11058696B2/en active Active
-
2021
- 2021-05-04 US US17/307,138 patent/US11701373B2/en active Active
- 2021-07-20 CY CY20211100656T patent/CY1124355T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017532294A5 (https=) | ||
| JP6474068B2 (ja) | ２−アミノピリミジン系化合物およびその薬物組成物と使用 | |
| JP6952695B2 (ja) | インフルエンザウイルス複製の阻害剤、その適用方法および使用 | |
| JP2015514808A5 (https=) | ||
| JP2018516963A5 (https=) | ||
| JP2018535963A5 (https=) | ||
| JP2015504067A5 (https=) | ||
| JP2014521688A5 (https=) | ||
| JP2019509276A5 (https=) | ||
| JP2015501833A5 (https=) | ||
| JP2016517417A5 (https=) | ||
| JP2017504650A5 (https=) | ||
| JP2012519691A5 (https=) | ||
| JP2016530259A5 (https=) | ||
| JP2016503797A5 (https=) | ||
| RU2015127827A (ru) | Производные бензилиденгуанидина и их терапевтическое применение для лечения заболеваний, связанных с неправильным сворачиванием белков | |
| JP2016506960A5 (https=) | ||
| JP2009526761A5 (https=) | ||
| JP2018536648A5 (https=) | ||
| JP2017530959A5 (https=) | ||
| JP2016525130A5 (https=) | ||
| JP2016504400A5 (https=) | ||
| JP2014513134A5 (https=) | ||
| JP2013510825A5 (https=) | ||
| JP2013527243A5 (https=) |